Public Summary

Summary for ARTG Entry:	309886 Tri-Mag Supreme Powder
ARTG entry for	Medicine Listed
Sponsor	Designs For Health Pty Ltd
Postal Address	1 / 418 Pittwater Road, North Manly, NSW, 2100 Australia
ARTG Start Date	28/09/2018
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Tri-Mag Supreme Powder

Product Type	Single Medicine Product	**Effective Date**	17/07/2019

Permitted Indications

Helps convert (state food) into energy

Maintain/support energy production

Maintain/support bone health

Aids/assists healthy bone development/growth/building

Maintain/support bone mass/density/integrity

Maintain/support healthy muscle contraction function

Maintain/support muscle function

Maintain/support muscle relaxation

Aid/assist/helps glucose/sugar/carbohydrate metabolism

Decrease/reduce/relieve symptoms of premenstrual tension

Indication Requirements

Label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Powder
Route of Administration	Oral
Visual Identification	

Active Ingredients

acetyl levocarnitine hydrochloride	**23.59 mg/g**
glutamine	**100 mg/g**
levomefolate glucosamine	**53.38 microgram/g**
Equivalent: levomefolic acid	30 microgram/g
magnesium amino acid chelate	**122 mg/g**
Equivalent: magnesium	24.4 mg/g
magnesium glycerophosphate	**203.5 mg/g**
Equivalent: magnesium	25.4 mg/g
magnesium orotate	**309 mg/g**
Equivalent: magnesium	20.2 mg/g
mecobalamin (co-methylcobalamin)	**30 mg/g**
nicotinamide	**6 mg/g**
pyridoxal 5-phosphate	**14.608 mg/g**
Equivalent: pyridoxine	10 mg/g
riboflavin sodium phosphate	**8.22 mg/g**
Equivalent: riboflavin	6 mg/g
taurine	**120 mg/g**
thiamine hydrochloride	**6.728 mg/g**
Equivalent: thiamine	6 mg/g

Other Ingredients (Excipients)

citric acid
Flavour
Steviol glycosides

Public Summary